Company intelligence / Profile preview
Vivozon
Hwaseong, Gyeonggi, South Koreavivozon.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vivozon’s lead candidate, VVZ-149 (Opiranserin), discovered via its multi-target platform, has advanced to global Phase 3 clinical trials. The company emphasizes rapid and efficient drug discovery for pain and CNS indications using its proprietary technology. It has received US FDA fast track designation for at least one program.
- Therapeutic areas
- Neurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Vivozon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivozon.